Biogen Inc (BIIB) : Fjarde Ap-fonden Fourth Swedish National Pension Fund scooped up 1,477 additional shares in Biogen Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Oct 14, 2016. The investment management firm now holds a total of 51,627 shares of Biogen Inc which is valued at $14,997,644.Biogen Inc makes up approximately 0.33% of Fjarde Ap-fonden Fourth Swedish National Pension Fund’s portfolio.
Other Hedge Funds, Including , National Pension Service boosted its stake in BIIB in the latest quarter, The investment management firm added 11,377 additional shares and now holds a total of 141,862 shares of Biogen Inc which is valued at $41,210,911. Biogen Inc makes up approx 0.34% of National Pension Service’s portfolio.Community Trust Investment Co boosted its stake in BIIB in the latest quarter, The investment management firm added 25 additional shares and now holds a total of 1,451 shares of Biogen Inc which is valued at $441,960. Biogen Inc makes up approx 0.06% of Community Trust Investment Co’s portfolio.Thompson Rubinstein Investment Management Inc Or reduced its stake in BIIB by selling 215 shares or 0.61% in the most recent quarter. The Hedge Fund company now holds 34,748 shares of BIIB which is valued at $10,583,893. Biogen Inc makes up approx 4.04% of Thompson Rubinstein Investment Management Inc Or’s portfolio.Arvest Bank Trust Division reduced its stake in BIIB by selling 44,375 shares or 50.43% in the most recent quarter. The Hedge Fund company now holds 43,621 shares of BIIB which is valued at $13,330,141. Biogen Inc makes up approx 1.12% of Arvest Bank Trust Division’s portfolio.
Biogen Inc closed down -3.91 points or -1.33% at $290.5 with 11,49,803 shares getting traded on Friday. Post opening the session at $295.63, the shares hit an intraday low of $290.13 and an intraday high of $297.34 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
On the company’s financial health, Biogen Inc reported $5.21 EPS for the quarter, beating the analyst consensus estimate by $ 0.52 according to the earnings call on Jul 21, 2016. Analyst had a consensus of $4.69. The company had revenue of $2894.00 million for the quarter, compared to analysts expectations of $2790.65 million. The company’s revenue was up 11.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $4.22 EPS.
Many Wall Street Analysts have commented on Biogen Inc. Biogen Inc was Downgraded by Jefferies to ” Hold” on Sep 6, 2016.
Biogen Inc. formerly Biogen Idec Inc. is a global biopharmaceutical company. The Company is focused on discovering developing manufacturing and delivering therapies for neurological autoimmune and hematologic disorders. The Company develops manufactures and markets products designed for the treatment of multiple sclerosis (MS) and hemophilia A and B. The Company’s marketed products include AVONEX PLEGRIDY TECFIDERA TYSABRI FAMPYRA for multiple sclerosis (MS) ALPROLIX for hemophilia B and ELOCTATE for hemophilia A among others. It also collaborates on the development and commercialization of RITUXAN (rituximab) which is a monoclonal antibody for the treatment of non-Hodgkin’s lymphoma chronic lymphocytic leukemia and other conditions and share profits and losses for GAZYVA which is for the treatment of chronic lymphocytic leukemia.